Literature DB >> 29850164

A case of different EGFR mutations in surgically resected synchronous triple lung cancer.

Naoki Haratake1, Mitsuhiro Takenoyama1, Makoto Edagawa1, Shinichiro Shimamatsu1, Ryo Toyozawa1, Kaname Nosaki1, Fumihiko Hirai1, Masafumi Yamaguchi1, Kenichi Taguchi2, Takashi Seto1, Yukito Ichinose1.   

Abstract

We describe a 77-year-old Japanese woman who presented with three nodule shadows in three different lobes of the right lung, without evidence of lymph node metastasis or distant metastasis. All three tumors were surgically resected. The pathological diagnosis was synchronous multiple primary lung cancer: pT2aN0M0, pStageIB. Based on a differing epidermal growth factor receptor (EGFR) mutation status, no lymph node metastasis, and no distant metastasis, the tumors were characterized as synchronous triple primary rather than intrapulmonary metastases. At eight months after surgery, a new lesion emerged in the right lower lobe. Given that the most advanced tumor had an EGFR del-19 mutation, the patient was orally administered afatinib. Since then, the treatment response of the patient has been assessed as stable disease (SD) for about two years. This is a very rare case of resected triple synchronous primary lung cancer on the same lung side in which the lesions all had a different EGFR mutation status, and this report highlights the clinical utility of surgical resection of multifocal lung nodules without lymph node metastasis or distant metastasis in order to optimize therapy for patients with known driver mutations.

Entities:  

Keywords:  Triple lung cancer; epidermal growth factor receptor (EGFR); surgery

Year:  2018        PMID: 29850164      PMCID: PMC5949472          DOI: 10.21037/jtd.2018.03.105

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  13 in total

Review 1.  Approach to the ground-glass nodule.

Authors:  Frank C Detterbeck; Robert J Homer
Journal:  Clin Chest Med       Date:  2011-10-02       Impact factor: 2.878

2.  High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.

Authors:  Chunyan Wu; Chao Zhao; Yang Yang; Yayi He; Likun Hou; Xuefei Li; Guanghui Gao; Jingyun Shi; Shengxiang Ren; Haiqing Chu; Caicun Zhou; Jun Zhang; Gerald Schmid-Bindert
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

3.  Synchronous primary lung cancer and epidermal growth factor receptor mutation.

Authors:  Edmond S K Ma; Paul N M Cheng; Chris L P Wong; Anthony P C Yim
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer.

Authors:  Stephen J Murphy; Marie-Christine Aubry; Faye R Harris; Geoffrey C Halling; Sarah H Johnson; Simone Terra; Travis M Drucker; Michael K Asiedu; Benjamin R Kipp; Eunhee S Yi; Tobias Peikert; Ping Yang; George Vasmatzis; Dennis A Wigle
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

6.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Authors:  Zhi-Yong Chen; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Xue-Ning Yang; Zhi-Hong Chen; Jin-Ji Yang; Qing Zhou; Hong-Hong Yan; She-Juan An; Hua-Jun Chen; Ben-Yuan Jiang; Tony S Mok; Yi-Long Wu
Journal:  Oncologist       Date:  2012-06-06

7.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Authors:  Yi-Long Wu; Caicun Zhou; Cheng-Ping Hu; Jifeng Feng; Shun Lu; Yunchao Huang; Wei Li; Mei Hou; Jian Hua Shi; Kye Young Lee; Chong-Rui Xu; Dan Massey; Miyoung Kim; Yang Shi; Sarayut L Geater
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

8.  The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification.

Authors:  Frank C Detterbeck; Andrew G Nicholson; Wilbur A Franklin; Edith M Marom; William D Travis; Nicolas Girard; Douglas A Arenberg; Vanessa Bolejack; Jessica S Donington; Peter J Mazzone; Lynn T Tanoue; Valerie W Rusch; John Crowley; Hisao Asamura; Ramón Rami-Porta
Journal:  J Thorac Oncol       Date:  2016-03-03       Impact factor: 15.609

9.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

10.  Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation.

Authors:  Kenichi Suda; Isao Murakami; Hui Yu; Kim Ellison; Masaki Shimoji; Carlo Genova; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-05-31       Impact factor: 15.609

View more
  2 in total

1.  Clinical Features and Surgical Treatment of Synchronous Multiple Primary Lung Adenocarcinomas With Different EGFR Mutations.

Authors:  Rirong Qu; Fan Ye; Dehao Tu; Yixin Cai; Xiangning Fu
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

Review 2.  Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer.

Authors:  Chi-Lu Chiang; Ping-Chung Tsai; Yi-Chen Yeh; Yuan-Hung Wu; Han-Shui Hsu; Yuh-Min Chen
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.